NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Orchestra BioMed Holdings, Inc. (OBIO) Stock Analysis

Orchestra BioMed Holdings, Inc. (OBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OBIO

$5.81

−$0.02 (−0.26%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OBIO with… →

OBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$5.83
Previous Close
$5.82
Day's Range
5.57–5.85
52-Week Range
3.46–6.50
Volume
485.95K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.52
Valuation
Market Cap
$348.91M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.86
Financials (FY)
Revenue (FY)
$33.48M+1,169.22%
Net Income (FY)
−$52.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
−184.60%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
60.11M
1-Year Return
+49.23%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
317.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OBIO closed at $5.81, +49.23% over 1 year.

Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalization of $348.91M.

In fiscal 2025, OBIO reported revenue of $33.48M.

OBIO Stock Return by Calendar Year

Orchestra BioMed Holdings, Inc. (OBIO) return since Aug 2020: what $10,000 became

1 year
$10,000 $14,923
+49.23%
5 years
$10,000 $5,902
−40.98%
Since Aug 2020
$10,000 $5,092
−49.08%

If you had invested $10,000 in Orchestra BioMed Holdings, Inc. (OBIO) at the close on August 4, 2020, the earliest close on record here, it would have been worth $5,092 at the close on October 21, 2026: −49.08% in total, −10.29% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+39.88%
2025+3.75%
2024−56.19%
2023−8.52%
2022−0.99%
2021−21.31%
2020 (partial year)+12.37%

As of October 21, 2026.

OBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$33.48M−$52.70M−157.4%
2024$2.64M−$61.02M−2,313.3%
2023$2.76M−$49.12M−1,779.7%
2022$3.53M−$33.61M−951.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$33.48M$33.29M−$51.81M−$52.70M−157.4%
2024$2.64M$2.43M−$64.30M−$61.02M−2,313.3%
2023$2.76M$2.57M−$51.51M−$49.12M−1,779.7%
2022$3.53M$3.32M−$32.66M−$33.61M−951.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OBIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricOBIOBiotechnology medianvs median
P/S ratio10.9113.3018% below
Profit margin−184.60%−38.31%146.3 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Orchestra BioMed Holdings, Inc. (OBIO) is capitalised at $348.91M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 86 employees.

The most recent close on file for OBIO is $5.81, dated October 21, 2026. That is −$0.02 (−0.26%) against the previous close. The 52-week range on file runs from $3.46 to $6.50. The latest close sits 67.77% above that 52-week low.

Financial Health

In fiscal 2025, Orchestra BioMed Holdings, Inc. reported revenue of $33.48M. Against the prior fiscal year total of $2.64M, that is a change of +1,169.22%. The same year closed with a net loss of $52.70M. The reported profit margin is −184.6%. That is 146.3 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −0.86.

Across the 4 fiscal years on file, revenue moves from $3.53M in 2022 to $33.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 10.91. On price-to-sales that is 17.95% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +49.23%. Measured over 5 years, that is −10.01% a year compounded. Beta against the wider market is reported at 0.52. Daily returns over the trailing 6 years annualize to a volatility of 83.95%.

Growth & Income

The record shows no dividend for OBIO.

The strongest complete calendar year on file is 2025 at +3.75%; the weakest is 2024 at −56.19%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +39.88% year to date.

Peer Comparison

Orchestra BioMed Holdings, Inc. (OBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Orchestra BioMed Holdings, Inc. OBIO $348.91M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Orchestra BioMed Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Visit website →